PVP Ventures Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
PVP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
PVP Ventures submitted Q1 FY26 results with standalone revenue from operations of ₹919.28 lakhs (vs nil in Q1 FY25) and total income of ₹1,275.85 lakhs, swinging to a net profit of ₹78.19 lakhs from a loss of ₹138.64 lakhs year-on-year. However, finance costs surged to ₹805.75 lakhs (vs ₹110.63 lakhs) due to amortization of NCD issuance costs after the company allotted ₹15,000 lakhs of secured NCDs in April 2025. The auditor flagged multiple emphasis-of-matter items: SEBI summons to the company, CEO and MD over past related-party transactions with erstwhile subsidiaries; a ₹21,843.49 lakh interest-free loan to related party NCCPL whose underlying land is under ED/SEBI attachment; a ₹2,800 lakh receivable from PHML (related party with negative net worth and continuing losses); pending GST, income tax, stamp duty and SEBI appeals; and a ₹669.69 lakh exceptional impairment on the HHT acquisition. The company also completed acquisitions of Optimus Oncology (56%) and Biohygea Global/Medilabs (52%) during the quarter.
Shareholders should weigh the SEBI investigation, large unprovided related-party exposures (over ₹24,600 lakhs to NCCPL and PHML combined), negative other equity of ₹(4,953.95) lakhs, and very weak debt service (0.14) and interest coverage (0.18) ratios, all of which signal elevated risk despite the return to quarterly profit.